Last reviewed · How we verify
Flecainide and verapamil
Flecainide and verapamil is a Small molecule drug developed by Maatschap Cardiologie Zwolle. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Flecainide and verapamil |
|---|---|
| Sponsor | Maatschap Cardiologie Zwolle |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment (NA)
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (NA)
- Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (NA)
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) (PHASE3)
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study (PHASE3)
- Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flecainide and verapamil CI brief — competitive landscape report
- Flecainide and verapamil updates RSS · CI watch RSS
- Maatschap Cardiologie Zwolle portfolio CI
Frequently asked questions about Flecainide and verapamil
What is Flecainide and verapamil?
Who makes Flecainide and verapamil?
What development phase is Flecainide and verapamil in?
Related
- Manufacturer: Maatschap Cardiologie Zwolle — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing